KOSDAQ

DongBang Medical Co., Ltd.’s Medical Thread ‘Miracue’ Draws Attention at Global Aesthetic Medicine Conference

Participation in the U.S. 'Aesthetic Show 2026'

[Edaily Reporter Hyera Lee ] #DongBang Medical Co., Ltd. announced on the 3rd that it recently participated in “The Aesthetic Show 2026,” an aesthetic medicine conference held in Las Vegas, USA, and introduced its own brand, Miracu.
The medical thread “Miracu.” (Photo courtesy of DongBang Medical Co., Ltd.)

Miracu is a cannula-integrated polydioxanone (PDO) thread product that encompasses a diverse lineup of threads—including Mono, Screw, and Cog—as well as dedicated cannulas. It is the first brand in the soft tissue adhesion product category to receive U.S. Food and Drug Administration (FDA) 510(k) Class II clearance.
DongBang Medical Co., Ltd., the world’s largest manufacturer of cannulas and PDO threads, showcased its Miracu cannula and PDO thread product line at the event under the slogan “See Everything. Miss Nothing,” emphasizing precise visibility and safety.
In particular, the company unveiled new needles and syringes designed specifically for skin boosters for the first time at this event. The specialized needle design, which aids in precise procedures, and the syringe’s ease of use drew significant interest from medical professionals in attendance. DongBang Medical Co., Ltd. conducted live demonstrations of Miracu products and provided training on procedural techniques for conference participants.
A DongBang Medical Co., Ltd. representative stated, “Through this participation, we aimed to convey both the reliability of our FDA-approved, clinically validated products and our expertise in precise procedures to medical professionals in the U.S. market.”

Economy

Corporation

IT·Science

Economy

A Semiconductor Fabless Company Founded by SK Hynix’s Youngest-Ever Executive [VC Cradle]

The biggest bottleneck for AI servers is memory. As the KV cache—where large language models (LLMs) store past computations—accumulates, the required memory capacity increases exponentially. This prob…
2026-07-04 09:00:07

Corporation

Genosco, Tax Risk?… “Lecraza Is ‘Royalty Income’; Its Value Remains Unchanged”

Concerns about “tax risks” have been raised in some quarters of the financial investment, pharmaceutical, and biotech markets regarding Genosco, a subsidiary of OSCOTEC Inc.(039200)specializing in new…
2026-07-04 08:31:02

IT·Science

Celltrion Pharm Inc. Builds a Plant, AriBio Secures Investment… K-Bio in ‘Expansion Mode’ [Weekly Bio Roundup]

As July began (June 29–July 3), the pharmaceutical and biotech industries turned their attention to Celltrion Pharm Inc.’s large-scale investment in production facilities and AriBio’s successful fundr…
2026-07-04 09:01:02